REVIEW article

Front. Cardiovasc. Med.

Sec. Atherosclerosis and Vascular Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1589629

This article is part of the Research TopicImmunity, Atherosclerosis and Cardiovascular Disease: An Interdisciplinary Approach to Cardiometabolic HealthView all 16 articles

Foamy Macrophages in Atherosclerosis: Unraveling the Balance Between Proand Anti-inflammatory Roles in Disease Progression

Provisionally accepted
  • 1Immunology Center of Georgia, Augusta University, Augusta, United States
  • 2Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia, United States

The final, formatted version of the article will be published soon.

Atherosclerosis is a complex immuno-metabolic disease characterized by lipid accumulation and chronic inflammation within arterial walls, leading to cardiovascular events such as stroke and myocardial infarction. Central to the disease are arterial plaques initiated by modified low-density lipoproteins (LDL), particularly oxidized LDL, deposited in the arterial intima. This deposition activates tissue-resident macrophages (TRMs), inducing a lipid-loaded "foamy" phenotype. Additionally, endothelial dysfunction promotes monocyte recruitment, differentiation into macrophages, and further foam cell formation. Foamy macrophages were initially identified as anti-inflammatory but have recently shown dual functionality, possibly depending on the disease stage and phenotype. Recent mouse and human studies also identified subsets of "foamy" macrophages with both pro and anti-inflammatory features. This review examines "foamy" macrophage complex roles and phenotypic diversity in atherosclerosis, emphasizing their potential as therapeutic targets to reduce inflammation and slow disease progression.

Keywords: Atherosclerosis, Inflammation, Macrophages, Foamy, TREM2, Olfr2

Received: 07 Mar 2025; Accepted: 16 Apr 2025.

Copyright: © 2025 Ijaz, Yarlagadda and Orecchioni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Marco Orecchioni, Immunology Center of Georgia, Augusta University, Augusta, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more